|
Olopatadine/mometasone
Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older.[1][2][3] It contains olopatadine hydrochloride and mometasone furoate monohydrate.[1][2] It is sprayed into the nose.[1][2] Common side effects include an unpleasant taste (dysgeusia).[1] It was approved for medical use in Australia in December 2019,[1][4] and in the United States in January 2022.[2] References
External links
|
||||||||||||||||||||||||||||||
